Rational design and synthesis of novel anti-prostate cancer agents bearing a 3,5-bis-trifluoromethylphenyl moiety

详细信息    查看全文

• 作者：Salvatore Ferla^&dagger ; ; Marcella Bassetto ; ^&dagger ; ; ^{bassettom@cardiff.ac.uk" class="auth_mail" title="E-mail the corresponding author} ; Fabrizio Pertusati^&dagger ; ; Sahar Kandil ; Andrew D. Westwell ; Andrea Brancale ; Christopher McGuigan
• 关键词：Homology modelling ; Rational drug design ; Prostate cancer ; Androgen-receptor
• 刊名：Bioorganic & Medicinal Chemistry Letters
• 出版年：2016
• 出版时间：1 August 2016
• 年：2016
• 卷：26
• 期：15
• 页码：3636-3640
• 全文大小：849 K

文摘

Prostate cancer is a major cause of male death worldwide and the identification of new and improved treatments is constantly required. Among the available options, different non-steroidal androgen receptor (AR) antagonists are approved also to treat castration-resistant forms. Most of these drugs show limited application due to the development of resistant mutants of their biological target.

Following docking-based studies on a homology model for the AR open antagonist conformation, a series of novel 3,5-bis-trifluoromethylphenyl compounds was designed with the aim to improve the antiproliferative activity of anti-androgen drugs bicalutamide and enzalutamide. The new structural modifications might impede the receptor to adopt its closed agonist conformation also in the presence of adaptive mutations.

Among the novel compounds synthesised, several displayed significantly improved in vitro activity in comparison with the parent structures, with IC₅₀ values in the low micromolar range against four different prostate cancer cell lines (LNCaP, VCaP, DU-145, 22Rv1). Selected hits demonstrated full AR antagonistic behaviour and promising candidates for further development were identified.